Brain, Vol. 112, No. 1, 133-146, 1989
© 1989 Oxford University Press
research-article |
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
I. CLINICAL COURSE AND DISABILITY
Department of Clinical Neurological Sciences, University of Western Ontario London, Ontario, Canada
Correspondence to:
Correspondence to: Dr G. C. Ebers, Department of Clinical Neurological Sciences, University Hospital, PO Box 5339, London, Ontario N6A 5A5, Canada
The outcome of multiple sclerosis (MS), assessed according to the Kurtzke Disability Status Scale (DSS), was reviewed in 1,099 consecutive patients followed in London, Canada, between 1972 and 1984. A geographically based subgroup of 196 patients representing 90% of Middlesex County MS patients as well as a group of 197 patients seen from onset of disease were separately analysed. The clinical course was progressive from onset in 33% of the total population and in 28% of the Middlesex County subgroup Of those with duration of 6–10 yrs, 30–40% with initially remitting disease developed progressive MS. The cross-sectional distribution of disability was bimodal with peaks at DSS 1 (no disability) and DSS 6 (assistance required for walking). Actuarial analysis showed that the median time to reach DSS 6 from onset of MS was 14.97±0.31 yrs in the total population and 9.42±0.44 yrs in the ‘seen from onset’ subgroup Survival was minimally altered; 87% of patients followed up to 40 yrs were still alive, although ascertainment of cases with this duration of MS was incomplete Data describing the rate at which disability develops after the onset of a progressive phase of MS are also presented. The implications of these data in planning and interpretation of clinical therapeutic trials are discussed.
Received January 12, 1988. Revised May 10, 1988. Accepted June 1, 1988.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. P. Thompson, K. Noyes, E. R. Dorsey, S. R. Schwid, and R. G. Holloway Quantitative risk-benefit analysis of natalizumab Neurology, July 29, 2008; 71(5): 357 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Optic Neuritis Study Group Multiple Sclerosis Risk After Optic Neuritis: Final Optic Neuritis Treatment Trial Follow-up Arch Neurol, June 1, 2008; 65(6): 727 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Miller, V. Spada, D. Beerkircher, and R. R. Kreitman Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing--remitting multiple sclerosis Multiple Sclerosis, May 1, 2008; 14(4): 494 - 499. [Abstract] [PDF]
|
|
|
|
 |
|
 S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al. B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis N. Engl. J. Med., February 14, 2008; 358(7): 676 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.S. Meier, H.L. Weiner, and C.R.G. Guttmann MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1956 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dutta, J. McDonough, A. Chang, L. Swamy, A. Siu, G. J. Kidd, R. Rudick, K. Mirnics, and B. D. Trapp Activation of the ciliary neurotrophic factor (CNTF) signalling pathway in cortical neurons of multiple sclerosis patients Brain, October 1, 2007; 130(10): 2566 - 2576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Leray, S. Morrissey, J. Yaouanq, M. Coustans, E. Le Page, J. Chaperon, and G. Edan Long-term survival of patients with multiple sclerosis in West France Multiple Sclerosis, August 1, 2007; 13(7): 865 - 874. [Abstract] [PDF]
|
|
|
|
|
|
J. Haas and O. R. Hommes A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 900 - 908. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Bergamaschi, S. Quaglini, M. Trojano, M. P. Amato, E. Tavazzi, D. Paolicelli, V. Zipoli, A. Romani, A. Fuiani, E. Portaccio, et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 757 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.A. Marrie, G. Cutter, T. Tyry, D. Campagnolo, and T. Vollmer Validation of the NARCOMS registry: diagnosis Multiple Sclerosis, July 1, 2007; 13(6): 770 - 775. [Abstract] [PDF]
|
|
|
|
|
|
V. Casado, L. Romero, L. Gubieras, L. Alonso, E. Moral, S. Martinez-Yelamos, A. Martinez-Yelamos, O. Carmona, and T. Arbizu An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain Multiple Sclerosis, July 1, 2007; 13(6): 800 - 804. [Abstract] [PDF]
|
|
|
|
|
|
C. Renoux, S. Vukusic, Y. Mikaeloff, G. Edan, M. Clanet, B. Dubois, M. Debouverie, B. Brochet, C. Lebrun-Frenay, J. Pelletier, et al. Natural History of Multiple Sclerosis with Childhood Onset N. Engl. J. Med., June 21, 2007; 356(25): 2603 - 2613. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dutta and B. D. Trapp Pathogenesis of axonal and neuronal damage in multiple sclerosis Neurology, May 29, 2007; 68(22_suppl_3): S22 - S31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Audoin, G. Davies, W. Rashid, L. Fisniku, A.J. Thompson, and D.H. Miller Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis Multiple Sclerosis, May 1, 2007; 13(4): 483 - 489. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Ness, D. Chabas, A. D. Sadovnick, D. Pohl, B. Banwell, B. Weinstock-Guttman, and for the International Pediatric MS Study Group Clinical features of children and adolescents with multiple sclerosis Neurology, April 17, 2007; 68(16_suppl_2): S37 - S45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.A. Woolmore, M. Stone, E.M. Pye, J.M. Partridge, M. Boggild, C. Young, P.W. Jones, A.A. Fryer, C.P. Hawkins, and R.C. Strange Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation Multiple Sclerosis, April 1, 2007; 13(3): 369 - 375. [Abstract] [PDF]
|
|
|
|
|
|
B. Stankoff, S. Mrejen, A. Tourbah, B. Fontaine, O. Lyon-Caen, C. Lubetzki, and M. Rosenheim Age at onset determines the occurrence of the progressive phase of multiple sclerosis Neurology, March 6, 2007; 68(10): 779 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Giesser, J. Beres-Jones, A. Budovitch, E. Herlihy, and S. Harkema Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study Multiple Sclerosis, March 1, 2007; 13(2): 224 - 231. [Abstract] [PDF]
|
|
|
|
|
|
D. M. Wingerchuk, S. J. Pittock, C. F. Lucchinetti, V. A. Lennon, and B. G. Weinshenker A secondary progressive clinical course is uncommon in neuromyelitis optica Neurology, February 20, 2007; 68(8): 603 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Debouverie, C. Lebrun, S. Jeannin, S. Pittion-Vouyovitch, T. Roederer, and H. Vespignani More severe disability of North Africans vs Europeans with multiple sclerosis in France Neurology, January 2, 2007; 68(1): 29 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]
|
|
|
|
|
|
H Butzkueven, J Chapman, E Cristiano, F Grand'Maison, M Hoffmann, G Izquierdo, D Jolley, L Kappos, T Leist, D Pohlau, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 769 - 774. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos, A. Traboulsee, C. Constantinescu, J. -P. Eralinna, F. Forrestal, P. Jongen, J. Pollard, M. Sandberg-Wollheim, C. Sindic, B. Stubinski, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology, September 26, 2006; 67(6): 944 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tremlett and V. Devonshire Is late-onset multiple sclerosis associated with a worse outcome? Neurology, September 26, 2006; 67(6): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Young, C. Lederer, K. Eder, M. Daumer, A. Neiss, C. Polman, L. Kappos, and on behalf of the Sylvia Lawry Centre for Multiple Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology, September 12, 2006; 67(5): 804 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. West, M. Wyatt, A. High, A. Bostrom, and E. Waubant Are initial demyelinating event recovery and time to second event under differential control? Neurology, September 12, 2006; 67(5): 809 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trojano, P. Russo, A. Fuiani, D. Paolicelli, E. Di Monte, E. Granieri, G. Rosati, G. Savettieri, G. Comi, P. Livrea, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 578 - 585. [Abstract] [PDF]
|
|
|
|
|
|
C L Martin, B A Phillips, T J Kilpatrick, H Butzkueven, N Tubridy, E McDonald, and M P Galea Gait and balance impairment in early multiple sclerosis in the absence of clinical disability Multiple Sclerosis, September 1, 2006; 12(5): 620 - 628. [Abstract] [PDF]
|
|
|
|
|
|
K H Chang, R K Lyu, C M Chen, W C Hsu, Y R Wu, S T Chen, and L S Ro Clinical characteristics of multiple sclerosis in Taiwan: a cross-sectional study Multiple Sclerosis, August 1, 2006; 12(4): 501 - 506. [Abstract] [PDF]
|
|
|
|
|
|
O. H. Kantarci, L. F. Barcellos, E. J. Atkinson, P. P. Ramsay, R. Lincoln, S. J. Achenbach, M. De Andrade, S. L. Hauser, and B. G. Weinshenker Men transmit MS more often to their children vs women: the Carter effect. Neurology, July 25, 2006; 67(2): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. DeLuca, K. Williams, N. Evangelou, G. C. Ebers, and M. M. Esiri The contribution of demyelination to axonal loss in multiple sclerosis Brain, June 1, 2006; 129(6): 1507 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inglese Multiple sclerosis: new insights and trends. AJNR Am. J. Neuroradiol., May 1, 2006; 27(5): 954 - 957. [Full Text] [PDF]
|
|
|
|
|
|
M Daumer, L M Griffith, W Meister, R A Nash, and J S Wolinsky Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation Multiple Sclerosis, April 1, 2006; 12(2): 174 - 179. [Abstract] [PDF]
|
|
|
|
|
|
S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 611 - 614. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 614 - 619. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 899 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta, E.-W. Radue, F. D. Lublin, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med., March 2, 2006; 354(9): 911 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease Brain, March 1, 2006; 129(3): 584 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Confavreux and S. Vukusic Age at disability milestones in multiple sclerosis Brain, March 1, 2006; 129(3): 595 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF]
|
|
|
|
|
|
B A Kallmann, S Fackelmann, K V Toyka, P Rieckmann, and K Reiners Early abnormalities of evoked potentials and future disability in patients with multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 58 - 65. [Abstract] [PDF]
|
|
|
|
|
|
H. Tremlett, D. Paty, and V. Devonshire Disability progression in multiple sclerosis is slower than previously reported Neurology, January 24, 2006; 66(2): 172 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J P A Samijn, P A W te Boekhorst, T Mondria, P A van Doorn, H Z Flach, F G A van der Meche, J Cornelissen, W C Hop, B Lowenberg, and R Q Hintzen Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 46 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients Multiple Sclerosis, December 1, 2005; 11(6): 626 - 634. [Abstract] [PDF]
|
|
|
|
|
|
V de Groot, H Beckerman, G J Lankhorst, C H Polman, and L M Bouter The initial course of daily functioning in multiple sclerosis: a three-year follow-up study Multiple Sclerosis, December 1, 2005; 11(6): 713 - 718. [Abstract] [PDF]
|
|
|
|
|
|
A. Kutzelnigg, C. F. Lucchinetti, C. Stadelmann, W. Bruck, H. Rauschka, M. Bergmann, M. Schmidbauer, J. E. Parisi, and H. Lassmann Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain, November 1, 2005; 128(11): 2705 - 2712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Marrie, G. Cutter, T. Tyry, O. Hadjimichael, D. Campagnolo, and T. Vollmer Changes in the ascertainment of multiple sclerosis Neurology, October 11, 2005; 65(7): 1066 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R H. Lazeron, J B Boringa, M Schouten, B M. Uitdehaag, E Bergers, J Lindeboom, M J Eikelenboom, P H Scheltens, F Barkhof, and C H Polman Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 524 - 531. [Abstract] [PDF]
|
|
|
|
|
|
M. Iskedjian, J. H Walker, T. Gray, C. Vicente, T. R Einarson, and A. Gehshan Economic evaluation of Avonex(R) (interferon beta-1a) in patients following a single demyelinating event Multiple Sclerosis, October 1, 2005; 11(5): 542 - 551. [Abstract] [PDF]
|
|
|
|
|
|
J Haas, M Maas-Enriquez, and H P Hartung Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years Multiple Sclerosis, October 1, 2005; 11(5): 562 - 567. [Abstract] [PDF]
|
|
|
|
|
|
M. Sandberg-Wollheim, D. Frank, T. M. Goodwin, B. Giesser, M. Lopez-Bresnahan, M. Stam-Moraga, P. Chang, and G. S. Francis Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis Neurology, September 27, 2005; 65(6): 802 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Oral Presentations Multiple Sclerosis, September 1, 2005; 11(5_suppl): S1 - S182. [PDF]
|
|
|
|
|
|
M. Soilu-Hanninen, J. O. Koskinen, M. Laaksonen, A. Hanninen, E. -M. Lilius, and M. Waris High sensitivity measurement of CRP and disease progression in multiple sclerosis Neurology, July 12, 2005; 65(1): 153 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Leary, B Porter, and A J Thompson Multiple sclerosis: diagnosis and the management of acute relapses Postgrad. Med. J., May 1, 2005; 81(955): 302 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H.S.R. Roxburgh, S. R. Seaman, T. Masterman, A. E. Hensiek, S. J. Sawcer, S. Vukusic, I. Achiti, C. Confavreux, M. Coustans, E. le Page, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity Neurology, April 12, 2005; 64(7): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wehman-Tubbs, S. H. Yale, and L. A. Rolak Insight into Multiple Sclerosis Clin. Med. Res., February 1, 2005; 3(1): 41 - 44. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al. Identifying and treating patients with suboptimal responses Neurology, December 28, 2004; 63(12_suppl_6): S33 - S40. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Stuart Current clinical perspectives on the treatment of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S1 - S2. [Full Text]
|
|
|
|
|
|
W. H. Stuart and P. Vermersch Concomitant therapy for multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S28 - S34. [Abstract] [Full Text] |